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Abstract 
This paper focuses on business models and value chains to analyse sectoral 
innovation systems involving synthetic biology and gene editing, as 
potentially disruptive platform technologies in the life sciences. In the 
context of industrial biotechnology, we propose that the extent to which an 
innovation is expected to be disruptive, and the location of that disruption in 
existing value chains, are relevant to policy decision making on how to 
govern innovative technologies. Policy decisions on how to regulate or 
support an innovative technology will be among the most important factors 
determining the extent to which it is able to deliver its disruptive potential, 
leading to sectoral transformations through new business models and value 
chains. This mode of thinking about disruption and innovation could be 
incorporated in standard procedures for policy makers to guide decisions 
designed to support translation from basic scientific research to societally 
useful products and processes. 
1. Introduction 
A useful understanding of innovation in the life sciences can be built (Wield et 
al., 2017) on integrating the perspectives of:  
• Scientists and innovators, working in universities, public and private 
research institutes, large and small companies, often involving networks 
and partnerships; 
• Policy makers and regulators at national and international levels; and 
• Citizens and stakeholders (the latter including patient interest groups 
and other advocacy organisations). 
This triangular relationship has formed the basis of the research programme of 
the Innogen Institute, as reflected in several of the articles in this issue. It has 
evolved since 2002 to become an interdisciplinary methodology designed to 
support better translation of basic scientific research to societally and 
economically valuable innovation, by identifying enablers and blockers of 
effective translation and key pressure points where specific actions can be most 
effective (Chataway et al., 2006; Milne and Tait, 2009; Mittra, 2015; Tait, et al., 
2002; Tait, 2007). The approaches and tools developed as part of this overall 
methodology, and the foundational research itself, are important to, and cited 
by, an unusually wide range of disciplines (Rafols and Costas, 2012) and this 
body of work has been influential on innovation and regulatory policy making 
for new technologies, particularly in life sciences (Mittra et al., 2015; Omidvar et 
al. 2014; Tait et al. 2017; Tait, 2016; Tait et al. 2014).  
2 
 
Among the tools and approaches developed as part of the Innogen 
methodology1, this paper concentrates on Strategic Planning for Advanced 
Technology Innovation Systems (STRATIS) (Wield et al. 2017) which focuses on 
business models and value chains, as components of company innovation 
strategies and related support policies, particularly for disruptive innovations. 
Illustrative points are taken from industrial biotechnology and innovations 
arising from basic research on synthetic biology and gene editing. 
Governments are increasingly concerned to reap the benefits of the basic 
research that they fund, particularly the highly significant benefits that can 
emerge from successful translation of a disruptive innovation, and for that to 
succeed they will need to have a better understanding of the nature of 
disruptive innovation itself, the circumstances that can stop it in its tracks or 
lead companies to migrate to another government’s jurisdiction, and where in 
an overall value chain to focus policy attention.   
This paper considers the influence of potentially disruptive discoveries in life 
sciences on specific business sectors involved in an overall value chain. It aims 
to help policy makers to predict when, how and where scientific discoveries 
could potentially have a disruptive influence and how specific policies could 
support or inhibit such outcomes. Other factors that can influence these 
processes, such as regulatory systems, stakeholder preferences and market 
influences are dealt with in other publications (Banda et al. 2019 (in press) (this 
journal issue); Mastroeni et al. 2019 (in press) (this journal issue); Mittra and 
Tait 2012; Mittra et al. 2015; Scannell et al 2019 (in press) (this journal issue); 
Tait et al. 2017). 
Section 2 introduces our approach to sectoral innovation systems as applied to 
potentially disruptive technologies in the life sciences whilst section 3 
emphasises the need to differentiate between incremental and disruptive 
technologies in policy making. Section 4 focuses on the sectoral location of 
disruption and in section 5 we illustrate some of the challenges that disruptive 
innovation may face based on the analysis of two potentially disruptive 
technologies – synthetic biology and gene editing. Section 6 describes how a 
better understanding of the processes of disruptive innovation can be applied to 
improve policy making for innovation support. 
2. Sectoral Innovation Systems 
Several systemic forms of innovation analysis have been developed (Tait, 2007), 
and STRATIS (Figure 1) relates most closely to Malerba’s (2004) ‘sectoral 
innovation systems’ approach. It uses three levels of analysis: (i) sector-specific 
business models and value chains, (ii) the innovation ecosystem within which 
the value chains are embedded, and (iii) future interactions that will determine 
the success or failure of innovative developments (Wield et al. 2017). We define 
the key elements of this form of analysis as follows. 
Business model. 
The business model represents the processes by which firms within a 
common sector create, capture and deliver value from a set of 
                                                     
1 https://www.innogen.ac.uk/downloads/Innogen-Institute-Research-Outline.pdf 
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technological opportunities. Within a sector or sub-sector there will be a 
generic business model, or models, designed around a common set of 
innovative developments, shaped by similar factors within the 
innovation ecosystem.  
Value chain. 
Most advanced technological innovation takes place through a value 
chain that requires carefully orchestrated collaboration of several 
companies with different business models, in parallel and/or in 
sequence to take an innovative development from conception to market. 
In some cases, a significant portion of the value chain can be located 
within a large multinational company with a single complex business 
model. 
Innovation ecosystem. 
The innovation ecosystem encompasses the wider economic, regulatory, 
societal and political context within which a value chain is embedded. It 
includes the external factors that will either enable or constrain the 
ability of companies involved in the value chain to implement their 
business models and to cooperate nationally and internationally to 
create and deliver value. 
The large arrows in Figure 1, indicating the system, the system’s environment 
and models of the system’s behaviour, relate to a systemic analysis that 
identifies the system of interest as the business models and value chain that are 
part of  the STRATIS analysis and are largely under the strategic control of the 
companies developing an innovation, and the factors in the system’s 
environment (the innovation ecosystem) that will affect companies’ decision 
making, over which they can have very little influence (e.g. regulatory or patent 
systems). At the highest level of analysis, qualitative or quantitative scenarios 
can be used to model the behaviour of the system under the influence of 
different internal company decisions and external ecosystem influences.  
STRATIS is designed to support decision making at various levels: (i) individual 
companies developing a business model for a specific innovation; (ii)groups of 
firms involved in strategy development for a sectoral value chain; (iii) analysts 
evaluating the impact of ecosystem factors such as markets, regulations or 
stakeholder actions as enablers or constraints on innovation trajectories (Mittra 
and Tait, 2012; Mittra et al, 2015); (iv) policy makers concerned to support 
disruptive innovation that can contribute to societal needs and wants and 
national economic prosperity (HM Government 2017; Tait et al. 2017); and (v) 
venture capitalists and others seeking information relevant to their investment 
decisions.  
The focus on a sectoral innovation system approach is relevant here because of 
the importance of a common set of business models as the defining 
characteristic of a sector, whereby incumbent company business models and 
value chains act as a welcoming environment for incremental innovations and 
an often-hostile one for a disruptive innovation that would potentially make 
them redundant.  
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Figure 1. STRATIS approach 
 
 
3. The disruptive–incremental distinction as a basis for innovation policy 
decision making 
3.1 Defining and analysing disruptive innovation 
The UK Industrial Strategy White Paper (HM Government 2017) recognises the 
need to support new industry sectors that will be disruptive of established ways 
of working and will ensure that the innovations on which these sectors will be 
based are not unnecessarily inhibited. It also recognises the important role 
played by incremental innovations that will improve our international 
competitiveness in existing industry sectors. Incremental and disruptive 
innovation are defined here as follows: 
Incremental innovation fits well with the current business model of a 
firm. It generates competitive advantage and contributes to the economy 
through more efficient use of resources, or elimination of wasteful or 
environmentally damaging practices, but will not lead to sectoral 
transformations. 
Disruptive innovation involves discontinuities in innovation pathways, 
requires new areas of research and development (R&D), creation of new 
modes of production and/or new markets. It can lead to sectoral 
transformations and the displacement of incumbent companies, or the 
creation of entirely new sectors, all with significant societal and 
economic benefits. There is often no pre-existing business model on 
which to build a strategy for disruptive innovation and there may also be 
a need to create a new value chain, or a new role for the emerging 
technology in an existing value chain.  
The concept of disruptive innovation relates to the observation that innovation 
arises from new scientific or engineering discoveries and progresses through 
periodic Schumpeterian waves of creative destruction, involving discontinuities 
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in innovation pathways which are regarded as the driving force behind the 
market system (Rothaermel 2000). Against this background, the paper by Tait 
(2007) analysed the disruptive potential of life science-related innovations in 
three sectors, agro-biotechnology, pharmaceuticals and stem cell therapies. In 
each case, rather than experiencing the expected disruption, incumbent 
multinational companies had demonstrated surprising resilience in the face of 
several waves of potentially disruptive scientific discoveries. This is in sharp 
contrast to the experience of the information and communication technologies 
(ICT) sector which has experienced several such waves of disruption arising 
from hardware and software innovations over the same timescale. 
The most influential exponent of the Theory of Disruptive Innovation, Clayton 
Christensen, has described it as starting from two market-related footholds: (i) 
low end footholds which exist because incumbents try to provide their most 
demanding customers with ever-improving products, opening the door to 
disrupters with a ‘good enough’ product to satisfy low-end customers; and (ii) 
new-market footholds where disrupters find a way to turn non-consumers into 
consumers (Christensen et al. 2015). Christensen’s analyses have been almost 
entirely in industry sectors that do not, as in life sciences, experience onerous 
and time consuming regulatory regimes. King and Baatartogtokh (2015) found 
77 cases of disruptive innovation described by Christensen and his co-workers, 
only two of which (endoscopic surgery and portable blood glucose meters) 
were related to life science innovation.  
Although Christensen’s theory has been extremely influential it has also had its 
critics. King and Baatartogtokh (2015) found that the theory of disruptive 
innovation has had only limited predictive power. Indeed Christensen et al. 
(2017) observed “Nearly a decade ago, The Innovator’s Prescription showed how 
disruption could transform healthcare. Yet unlike other industries, healthcare 
has been largely immune to the forces of disruptive innovation.” In a scenario 
analysis of the future of the pharmaceutical sector in 2030, Tait et al. (2007) 
predicted that disruption was eventually likely to come to the pharmaceutical 
sector through close interaction and possibly integration with major companies 
in the ICT sector, including the application of ICT sectoral business models to 
current challenges in the delivery of health care. This is now being realised as 
Apple, Google, Amazon and Facebook are disruptively entering the space of 
health research and delivery, offering new methods for collecting, storing and 
analysing health data (Sharon 2016). This reinforces our observation on the 
non-applicability of much of the writing on disruptive innovation to life science-
related sectors and reinforces the case for a new approach to analysis of this 
phenomenon in such cases. 
Tait (2007) attributed this resilience of the business models of multinational 
companies in life science-related areas largely to the existence of time-
consuming and expensive regulatory systems acting as a barrier to entry for 
small companies with disruptively innovative ideas, and more recent evidence 
has supported this view (Tait et al. 2017). Another important set of insights, as 
discussed in this paper, relates to the need to think constructively about which 
sectors are most likely to be disrupted by a particular innovation and to 
consider the location of the disruptive impact across an entire value chain 
which may involve several industry sub-sectors with different business models.   
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The above definitions of the terms ‘business model’, ‘value chain’, ‘innovation 
ecosystem’, ‘disruptive innovation’ and ‘incremental innovation’ clarify how we 
are interpreting them and how we link them systemically in this new form of 
analysis to understand both the factors that drive innovation in different 
directions and how innovation can be influenced by, and contribute to, 
government policy agendas.  
The definitions imply that incremental innovation should find an easy route to 
uptake in the companies whose business models it supports, while disruptive 
innovation faces many challenges but is also seen as an important part of the 
solution to greater national prosperity and international competitiveness (HM 
Government 2017). For these reasons, disruptive innovation is, or should be, 
the main focus of publicly-funded innovation support initiatives. 
3.2 Disruptive innovation is a slippery concept 
From the above discussion of the work of Christensen and others, it is clear that 
the concept of disruptive innovation cannot be straightforwardly extended to 
areas beyond ICT-like sectors in a way that would contribute to its status as a 
formal theory. However, it is a concept that is widely used in innovation and 
policy circles and there is a need to enrich it to support our understanding of 
how basic scientific research can most effectively be translated to innovative 
outcomes. The following two sector-related insights are important 
contributions to this enriched field of application of the disruptive innovation 
concept. 
(i) An innovation that is disruptive of the business model of one industry 
sector can be incremental for another. 
In the early stages of development of a disruptive innovation, as defined here, 
there will be no clear, pre-existing business model, and several existing sectors 
may have an interest in it. For example, when genetically modified (GM) crops 
were in the early stages of development in the 1980s, companies interested in 
the technology included many of the agrochemical companies then in business, 
Shell (interested in GM trees), Unilever (interested in cloned oil palm trees), and 
several large seed companies. GM technologies were most disruptive of the 
agrochemical company business model, across all stages of development from 
basic research, through later translational stages to manufacture, distribution 
and marketing. For most of the other companies in the mix, GM-related 
innovation would have had a relatively incremental impact on their pre-existing 
business models. The agrochemical companies faced another seriously 
disruptive challenge in the potential of GM crops to lead to significant 
reductions in the use of pesticides, the foundation of their business model at the 
time (Tait 2007). The agrochemical industry sector thus had a greater incentive 
than any of the others to gain control of this important, potentially disruptive 
innovation and they did so through the regulatory system, with the support of 
the policy community at the time (Tait and Levidow 1992, Tait 2007). 
(ii) An innovation can be disruptive for some of the sectors/business models 
contributing to an overall value chain, and neutral or incremental for 
others  
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To understand fully how to manage a disruptive innovation, it is important to 
consider its impact across an entire value chain and this element is also lacking 
in the disruptive innovation literature. The point is elaborated more fully in 
Section 4, but it can also be illustrated through the above GM crops example. In 
developing its new business models to incorporate this disruptive innovation, 
the agrochemical industry sector assumed that its value chain ended at the farm 
level (Tait and Chataway 2007). They failed to follow it through from the farm 
level to the food producers and distributors and eventually to citizens as 
consumers, and the fact that the technology proved to be so disruptive at this 
level was a major factor in the failure of this technology to achieve its disruptive 
potential in Europe.  
4. Contribution of synthetic biology and gene editing to innovation in 
industrial biotechnology. 
Synthetic biology and gene editing are frequently described as disruptive 
platform technologies that are expected to form the future basis of the 
bioeconomy and to transform production processes across a number of sectors 
(Datta 2016; Law 2015; Talbot 2016; Synthetic Biology Leadership Council 
(SBLC) 2016). However there are no examples yet where the concept of 
disruptive innovation has been applied to examples of such innovation in 
practice.  
The value of the UK bioeconomy was estimated recently to be £150 bn GVA, 
increasing by another £40 bn over the next decade and UK public investment in 
synthetic biology to date is over £300 million, supplemented by substantial 
private investment (Chambers et al. 2015; SBLC 2016). Continuing this trend, 
the 2018 bioeconomy strategy paper projected a doubling of the impact of the 
bioeconomy to £440 bn by 2030, much of it expected to be delivered through 
industrial biotechnology (HM Government 2018).  
In the current chemicals manufacturing sector, a broad range of chemical 
intermediates (ethylene, propylene, butadiene, benzene, toluene, xylenes) is 
manufactured on a very large scale by petro-chemicals based companies and 
sold further along the value chain to companies in sectors developing drugs, 
detergents, polymers, synthetic fabrics, flavours, fragrances, enzymes and food 
ingredients. The final products then reach market end-users via supermarket 
chains and other consumer outlets. These established value chains have evolved 
over a number of decades and encompass companies with different business 
models operating in parallel or in sequence (Figure 1).  
This is the value chain that is claimed to be open to disruption by innovations 
based on synthetic biology and gene editing, modifying micro-organisms and 
enabling fermentation-based production of high value chemical intermediates 
(Tait 2016). There are also longer-term prospects to develop chemicals that 
cannot currently be made at scale, or to build new classes of feedstock for 
fermentation-based processes.  
Driven by the impacts of climate change, many countries now have policies 
designed to minimise the use of fossil fuels by supporting the development of 
biologically sourced chemical intermediates (the bio-economy) and eliminating 
waste (the circular economy) (Tait 2016). In the short term, industrial 
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biotechnology production of chemical intermediates is unlikely to be 
competitive with the low cost, large scale manufacture of products such as 
butadiene and toluene from fossil fuels, but new market niches are emerging, 
for example in the production of more specialised and higher value 
intermediates such as industrial enzymes, lactic acid, 1,3-propanediol, and 
isoprenoids (US National Research Council (US NRC) 2015).  
Fermentation-based biofuel production is already in place on a significant scale. 
In 2016, global biofuel production amounted to approximately 82 bn metric 
tons oil equivalent, 70% of this in the USA and Brazil2. Further developments in 
this area are likely to arise using synthetic biology and gene editing to break 
down cellulose and lignin-based waste products to produce sugars as feedstock, 
among other things for biofuel production, contributing to the circular 
economy. Despite these impressive numbers, this level of biofuel production is 
still very far from beginning to disrupt the business models of the current 
producers of petrochemical based fuels for transport. It is an example of the use 
of government policy to support innovation that would otherwise be 
uncompetitive, to meet political and societal objectives (Nuffield Council on 
Bioethics 2011), in these cases based on the use of a carbon source that is 
surplus to requirements in the country concerned (corn in the USA and sugar in 
Brazil).  
The US NRC Report (2015) identifies four different business models/value 
chains likely to be involved in the future development of industrial 
biotechnology: 
(i) Vertically integrated business model: Research and design for bio-
manufacturing is performed by corporations that develop the entire 
process from feedstock sourcing to organism engineering to 
manufacturing and sales, e.g. bio-pharmaceuticals. 
(ii) Centralised production business model: Bio-manufacturing occurs in a 
small number of very large facilities that take advantage of economies 
of scale to deliver products with thin margins at large volumes to meet 
world demand, e.g. international scale brewers. 
(iii) Horizontally stratified value chain: Research and design for bio-
manufacturing is performed by different companies, each specialising 
in a different step along the production process, e.g. small and medium 
sized bio-based manufacturers of specialty chemical feedstocks (now 
emerging in the USA). 
(iv) Distributed production value chain: Bio-manufacturing occurs in many 
small scale facilities, using geographically co-located feedstocks and 
delivering products to meet local or niche markets, equivalent to micro-
breweries. 
Predictions of the disruptive impact of synthetic biology and gene editing 
platform technologies on innovation in industrial biotechnology have so far 
been too vague to be of value in projecting future technology outcomes or in 
                                                     
2 https://www.statista.com/statistics/274168/biofuel-production-in-leading-countries-in-oil-
equivalent/ 
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guiding policies to support innovation. This section applies the concepts 
outlined above to these NRC categories of business model or value chain. The 
key points here are that: for vertically integrated or centralised production, one 
company is in control of all stages of production, from the initial innovation 
platform through to formulation and marketing, based on a single overarching 
business model; whereas for horizontally stratified or distributed production, 
the focus is on an integrated value chain incorporating several different 
business models pertaining to the different types of company involved in the 
value chain.    
4.1 Business models - vertically integrated or centralised production  
These two types of business model are considered together because of the 
potential for overlap between them. Vertically integrated company business 
models are likely to be based on centralised production facilities and vice versa 
(Figure 2). 
 
Figure 2. Industrial Biotechnology Business Models – Vertically Integrated and 
Centralised Production 
 
 
Many pharmaceutical companies already use modified micro-organisms to 
manufacture complex bio-pharmaceuticals, using a vertically integrated 
business model. Synthetic biology and gene editing will enable these companies 
to continue with the same business model, but to use a modified organism to 
improve the efficiency and reliability of the biology-based process, and hence 
the affordability or the quality of the drug produced. The innovation process 
will be able to build on the skills already available within the company to 
produce high value biopharmaceutical products for existing high value global 
markets. The likely impact of synthetic biology or gene editing on these 
business models thus fits with the above definition of incremental innovation in 
the context of that type of company and business model. This is valid for 
pharmaceutical companies that have already faced the disruptive transition to 
fermentation-based manufacturing processes3. Where a pharmaceutical 
                                                     
3 This point could be seen as contradicting the observation below that chemical/fossil fuel-based 
manufacturers are unlikely to make the disruptive transition to fermentation based production 
methods. The incentive for the pharmaceutical companies to face this disruption lies in the very high 
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company still uses thermo-chemical manufacturing processes to produce its 
drugs, conversion to fermentation-based technology would of course be 
significantly disruptive.  
There are also large, centralised, vertically integrated companies in the US 
developing biofuel (ethanol) from maize with the support of government 
subsidies to encourage the use of this agricultural feedstock. Synthetic biology 
and gene editing will offer improvements in these processes through the re-
design of the organisms involved in fermentation in a way that will again be 
incremental in their impact on company business models.  
4.2 Value chains: Horizontally stratified or distributed production 
Figure 3 describes the value chains that are the target for innovation in 
industrial biotechnology, based on synthetic biology and gene editing, with 
different impacts, disruptive or incremental, in different locations across the 
value chain. 
Feeding in at the beginning of these value chains, a new type of SME has 
emerged, designing and delivering the novel engineered micro-organisms 
needed for fermentation-based manufacturing processes. These synthetic 
biology platform support companies are disruptively innovative in that there are 
no pre-existing business models that they can adopt – they are inventing new 
‘design and build’ approaches that have not existed on any scale until the past 
few years. As implied in Figure 1, they will either need to find a role for their 
business model in existing value chains or (more uncertain) collaborate with 
other companies in the design of entirely new value chains.  
 
Figure 3. Industrial Biotechnology Value Chains – Horizontally Stratified or 
Distributed Production 
 
                                                     
value of the bio-pharmaceutical products being developed and often the lack of any viable 
alternative manufacturing process. 
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Growth (or even viability) in this early platform support sector will depend on 
whether the next companies along the value chain (Figure 3), the incumbent 
specialty chemicals manufacturing companies with business models currently 
based on petrochemical raw materials are willing to take up the disruptive 
challenge of using synthetic biology and gene editing to develop the chemical 
feedstocks and advanced biological products of the future.  The formulators, at 
the next stage of the value chain, will continue to base their production on small 
molecule intermediates and the novel source of these molecules is unlikely to 
have any disruptive impact on their business models so the result of innovation 
based on synthetic biology and gene editing for these companies will be 
incremental (Figure 3). They will also continue to produce similar (but better) 
products for the same consumer markets as before, so again there may be no 
overall market disruption.  
4.3 A reality check 
Sections 4.1 and 4.2 describe the expected context for incorporation of 
innovation based on synthetic biology and gene editing into industrial 
biotechnology value chains. However, the future shape of this industry and its 
potential contributions to the bioeconomy and the circular economy will 
depend on the resultant of the factors outlined above and will inevitably be 
more messy than expected. We suggested (Section 3.2) that an innovation can 
be disruptive for one industry sector within a value chain (Figure 3) but neutral 
or incremental for another, and Tait et al. (2017) have observed that the 
smoothest route to market for a potentially disruptive technology is likely to be 
through the incumbent industry sector for which it will be least disruptive.  
For large scale petrochemicals-based producers of chemical intermediates, 
converting from fossil fuel based production to biotechnology based 
production, as projected in policy documents on the bioeconomy, would be 
seriously disruptive of their current business model, requiring new equipment, 
new staff skills and compliance with a new set of regulatory requirements. It is 
unlikely that the companies currently managing oil refineries would be willing 
or able to replace them with facilities based on bio-digesters and fermenters. 
The economics of production are also not conducive to such a change, given the 
current relatively low price of oil and some of the difficulties still to be 
overcome in achieving reliable fermentation-based manufacture of chemical 
intermediates (Cambridge Consultants 2018). There is thus unlikely to be any 
shift towards the bio-based direction from fossil fuel based manufacture in the 
foreseeable future and any policy initiative designed to support such an 
outcome is unlikely to succeed.  
The observation, that the smoothest route to market for a potentially disruptive 
technology is likely to be through the incumbent industry sector for which it 
will be least disruptive, would point to companies with business models 
currently based on large scale fermentation and brewing, producing enzymes 
and drinks for human consumption. All other things being equal, this would be 
the most logical sector to take up the innovation potential for the bioeconomy 
arising from synthetic biology and gene editing. However, for these companies 
there is potential market disruption, given that they would be serving very 
different markets from their current focus on the food and drink sector, and the 
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potential for consumer-generated reputational risk will discourage such a move 
by these companies.  
So there is a gap in the bio-based value chain that represents a new disruptive 
business niche for specialty chemicals manufacturing companies to begin 
developing moderate to high value chemical intermediates based on 
fermentation production processes using synthetic biology and gene editing-
enhanced micro-organisms. These new business models are likely to be SME-
based to begin with, with the potential for the companies to grow rapidly, to 
create an industrial biotechnology sector building on synthetic biology and gene 
editing. This trajectory is already well under way in the USA (US NRC 2015). 
One example of such a company with an intriguing business model, Intrexon4, 
describes itself as “committed to a better world through better DNA”™, with 
initiatives in food, environment, drugs/health, GM insects, energy products and 
consumer products, “ … designing and constructing . … single and multi-gene 
programs with predictable outcomes providing our collaborators a wealth of 
capabilities.” 
If investors understand the factors that will determine the success of different 
types of company planning to operate in industrial biotechnology value chains, 
these SMEs will benefit from the expectation that the occupants of the 
incumbent business sectors (petrochemicals and large scale brewing) have 
good reasons not to be planning to invest in this new, potentially disruptive 
technology. The new entrants will then be the next step along the value chain, 
using the products of the synthetic biology and gene editing platform support 
companies, and feeding their outputs either to the existing formulators or 
straight to an end-user market. In the longer run, depending on future oil prices 
and government policies to support non-fossil fuel based production, they may 
also be able to compete disruptively with the very large petrochemicals based 
producers by developing superior products (e.g. according to future climate 
change related criteria).  
If the gap identified here is not filled, past public and commercial investment in 
synthetic biology platform support companies will not deliver the expected 
returns, these companies could go out of business and there may be a risk that 
public sector investment in their early development will have been wasted.  
5. Conclusions 
Disruptive innovation is usually regarded as a rare, desirable, but ill-defined 
outcome of basic scientific research, distinguished from the much more 
common, also societally beneficial incremental innovation. Because of the 
potential gains for a national economy that hosts the next generation of 
disruptive innovations, many governments, including the UK, now have policies 
designed to support this outcome (HM Government 2017). This paper is seen as 
a contribution to future policy making, intended to improve the extent to which 
a nation is able to capitalise on any potentially disruptive outcomes from basic 
scientific research. 
                                                     
4 https://www.dna.com/ 
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The approach to understanding disruptive innovation introduced here focuses 
on the interactions among innovative technology developments, the business 
models of incumbent companies and of potential future companies, and the 
value chains to which they contribute. It attempts to foresight future company 
behaviour and innovation outcomes based on knowledge of these elements of 
the innovation ecosystem within which they are embedded.  
There is a common perception in policy circles that it is not possible to tell in 
the early stages of its development whether an innovative technology will be 
disruptive or incremental. This can be seen partly as a lack of recognition by 
policy makers of the extent to which their decisions are a determining factor in 
the future trajectory of an innovative technology platform (examples could be 
synthetic biology and gene editing as discussed in this paper or, in the ICT area, 
blockchain). Policy decisions on: what regulatory system to adopt for an 
innovative technology (Tait et al. 2017); which innovation support mechanisms 
to put in place; or how to measure success of a policy initiative and the 
timescale over which to monitor that success; will all contribute to the eventual 
innovation outcome and the extent of the disruption experienced.  
This is a question of intelligent foresight, with all the usual caveats about human 
foresighting capabilities. However, such predictions can be more accurate if 
based on an intimate knowledge of the technology itself and of the collaborating 
or competing industry sectors that could take on the role of developing and 
marketing it (Mittra et al. 2015; Tait 1993; Tait et al 2007). As indicated in 
Figure 1, a scenario analysis that incorporated all these factors to model the 
future behaviour of specific sectors of the economy under the impact of a 
disruptive innovation could guide policy makers on where to focus their 
attention to inform future policies. 
When a set of new technology developments is considered to be potentially 
disruptive, the above analysis leads to the following general recommendations 
for policy makers:   
i. Identify the target areas where the innovation concerned is expected to 
have a disruptive impact and the high-level policies to which it is 
relevant (e.g. the bioeconomy or the circular economy); 
ii. Map the relevant value chains, noting the sectors, the types of companies 
and the scale of the companies involved in the value chain, as for 
example in Figure 3; 
iii. Consider the extent to which the expected innovations will be disruptive 
or incremental for the companies involved in the current value chain, 
whether they will be willing to incorporate the innovation into their 
current business models or to displace their current business models 
with a new one, and what is likely to be the innovation outcome of these 
decisions; 
iv. Identify any gaps in future value chains that are likely to restrict the 
future operation of that value chain with the potential to stop 
development of the innovation concerned or to divert activity to a 
different value chain; 
14 
 
v. Consider what sectoral-level policies can support the value chain as a 
whole in delivering the higher level policies. 
Such questions could form the basis of a dialogue between policy makers, 
innovators and incumbent companies as part of the planning process for future 
innovation support policies. 
Considering these recommendations in the context of industrial biotechnology 
and its future development based on synthetic biology and gene editing, until 
recently innovation support initiatives have been largely targeted towards 
synthetic biology platform support companies, at the beginning of the value 
chain described in Figure 3. However, as noted in Section 4.3, a gap has been 
emerging in the part of the value chain that is currently occupied by 
petrochemicals-based specialty chemicals manufacturing companies with no 
clear candidates from that sector being willing to build disruptively innovative 
business models based on alternatives to fossil fuels. The logical policy 
conclusion would be that there is a need for policy initiatives to foster the 
emergence of new fermentation-based companies willing to fill the gap 
identified in the next generation value chain for industrial biotechnology.  
Relevant to this need the UK government, through initiatives set up under its 
Industrial Strategy and Bioeconomy Strategy (HM Government 2017, 2018) has 
announced investments of £125 million in initiatives to reduce plastic waste 
and support the development of biodegradable plastics. These initiatives could 
help to fill the gap identified in some industrial biotechnology value chains, 
albeit in one specific area of the much broader bioeconomy. However, there is 
no evidence that these funding decisions were based on any formal 
consideration of the support needs of disruptive innovative technologies in 
general or in the specific case of industrial biotechnology.  
The mode of thinking about innovation support policies introduced here could 
supplement current policy approaches and contribute to more creative policy 
dialogue between the key industry and policy players. It could lead to targeted 
cross-sectoral strategies that will deliver the necessary innovation support in a 
timely manner to the appropriate point in relevant value chains and enable the 
UK to retain more effectively the ‘first mover’ advantage it often has, arising 
from the high quality basic scientific research that it funds.  
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